You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

Displaying 1 - 10 of 8807 results
  1. Toxicology and Efficacy Studies of Intrathecal VersaMab-101 for spinal cord injury treatment

    SBC: VERSAPEUTICS INC            Topic: 106

    PROJECT SUMMARY/ABSTRACTSpinal cord injury (SCI) is estimated to affect between 249,000 and 363,000 Americans, with about 17,730 new injuries occurring each year. There are around 42000 SCI patients that are veterans in the United States. Nearly half of all SCIs occur in patients between the ages of 16 and 36, which results in individuals living with SCI for decades. The lifetime costs of living w ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  2. Neonatal EEG MOnitor (NEMO) Phase IIb

    SBC: QUANTUM APPLIED SCIENCE & RESEARCH INC            Topic: 101

    Abstract Neonatal seizures occur in over 14,000 newborns annually in the US, and are frequently associated with long-term deleterious consequences including intellectual disability, epilepsy, and other neurodevelopmental disabilities. Electroencephalography (EEG) is the only reliable means of detecting seizures; however, many Neonatal Intensive Care Units (NICUs) do not have the capability to do E ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  3. IND-enabling Preclinical Development of a Sustained-release Pritelivir Intravaginal ring for the Treatment and Prophylaxis of Genital Herpes

    SBC: AURITEC PHARMACEUTICALS, INC.            Topic: NIAID

    SUMMARY The broad, long-term goal of this project is to develop a pritelivir intravaginal ring (IVR) for the treatment and pre-exposure prophylaxis of genital herpes, a common problem that affects more than 30 million Americans. Recurrences are common and may be painful, and infection is life-long, yet few treatment options exist. Pritelivir is a promising α-helicase inhibitor that has been prove ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  4. Development of an oxygen delivery biotherapeutic for the preservation of myocardial function during pediatric cardiopulmonary bypass

    SBC: OMNIOX INC            Topic: NICHD

    1. PROJECT SUMMARY/ABSTRACT Omniox is developing a unique oxygen delivery protein, OMX, as a treatment to preserve myocardial and peripheral organ function and significantly reduce morbidity after neonatal cardiopulmonary bypass (CPB) during surgical correction of congenital heart disease (CHD). Of the ~40,000 children born annually with CHD, ~10,000 require urgent surgery to repair heart defects1 ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  5. Novel therapy for alcoholic liver disease-associated hepatorenal syndrome

    SBC: MITOPOWER LLC            Topic: 999

    Novel therapy for alcoholic liver disease-associated hepatorenal syndrome Abstract Alcoholic liver disease (ALD) results in over 400,000 hospitalizations each year in the US, with a portion of these patients developing hepatorenal syndrome with acute kidney injury (HRS-AKI). There are no current therapeutic options that specifically address the cellular dysfunction and systemic inflammatory respon ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  6. Developing and Automating an Extracellular Vesicle-Based Test for Early Detection of Hepatocellular Carcinoma

    SBC: EXIMIUS DIAGNOSTICS CORP            Topic: 102

    PROJECT SUMMARY Hepatocellular carcinoma (HCC) comprises 80-85% of primary liver cancers and frequently develops in patients with liver cirrhosis or chronic hepatitis B virus infection. HCC's poor prognosis is primarily due to advanced-stage diagnosis. Current clinical practice guidelines recommend biannual liver ultrasounds, with or without serum alpha-fetoprotein (AFP) testing, for at-risk patie ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  7. A Bedside Relational Agent to Improve Hematopoietic Cell Transplantation Outcomes in Cancer Patients

    SBC: CARE.COACH CORPORATION            Topic: 101

    Abstract Delirium, a major cause of falls, can occur in as many as 50% of cancer patients undergoing stem celltransplantation, resulting in up to 14 times greater chance of dying. Delirium risk can be mitigated and manyother outcomes of stem cell transplants can be improved through behavioral interventions delivered at thebedside through conversation, imagery, and audio. However, traditional means ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  8. Mitigation of Radiation Induced Gastrointestinal Syndrome.

    SBC: BCN BIOSCIENCES LLC            Topic: NIAID

    Abstract: Currently RAS has been considered a high value target in cancer drug development considering that over 30 percent of all human cancers – including 95% of pancreatic cancers and 45% of colorectal cancers — are driven by mutations of the RAS family of genes. The first clinical launch of a G12C KRAS inhibitor is Lumakras™ (sotorasib) from Amgen for non-small cell lung carcinoma and Mi ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  9. Development of World's First Fully Human Broad Spectrum Anti-Snake Venom

    SBC: Centivax Inc            Topic: NIAID

    ABSTRACT Snakebite envenoming poses a global risk to human health. For over 125 years, antivenoms have consisted of animal-derived polyclonal serum immunoglobulin G (IgG). In recent decades, IgG digested into antigen-binding fragments Fab(2) has been found to reduce some of the most severe side-effects of non-human antivenom. These antivenoms are obtained by immunizing horses or sheep with individ ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  10. Development of Coccidioides Cytokine Release Assay

    SBC: MIRAVISTA DIAGNOSTICS LLC            Topic: NIAID

    Coccidioidomycosis (CM) is an endemic mycosis caused by the fungi Coccidioides immitis and Coccidioides posadasii, which is native to arid regions of North and South America. It is estimated that up to 350,000 infections occur annually in the U.S. Additionally, up to a third of community acquired pneumonia cases in these areas are thought to be a result of CM. Morbidity associated with CM is subst ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government